Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in girls living with HIV

HPV in HIV Study Group

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)

Abstract

We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9-13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.
Original languageEnglish
Pages (from-to)595-597
JournalPediatric Infectious Disease Journal
Volume37
Issue number6
DOIs
Publication statusPublished - 2018

Cite this